The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The study met its primary endpoint with flying colors
The partnership also sets the stage for broader collaboration on rare disease treatments
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Subscribe To Our Newsletter & Stay Updated
